Hearing Loss Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with congenital (present from birth) hearing loss where hearing thresholds are 65 dB or worse, who have already received gene therapy with follow-up care, are planning to receive gene therapy, or have received a cochlear implant.
• Healthy participants with normal hearing (thresholds of 20 dB or better), broadly matched to the other groups by age and sex.
• People aged 6 months or older, of any gender.
• People whose first language is Mandarin Chinese.
• Participants (and their guardians) who are willing to give written consent, attend follow-up appointments at set time points, and cooperate with the research team's requirements.
• Participants who are able to communicate effectively with researchers, with help from a guardian if needed.
• Guardians who have a clear and realistic understanding of what the trial involves and what benefits might reasonably be expected.

Who may not be able to join:

• People with other ear conditions that could affect surgery outcomes or how results are interpreted — such as middle or inner ear structural abnormalities seen on CT or MRI scans in the past 3 months, nerve abnormalities in the ear, ear infections, or Meniere's disease.
• People with other serious conditions present from birth.
• People with severe ongoing illnesses or illnesses in an active stage, such as tuberculosis, active hepatitis B or C, active shingles (herpes zoster), pancreatitis, or kidney insufficiency.
• People with a weakened immune system, a history of immune deficiency, or a history of organ transplantation.
• People with a history of neurological or mental health conditions, such as epilepsy or dementia.
• People who a surgeon, anaesthetist, or designated medical professional considers to have reasons why surgery or anaesthesia would not be safe — for example, a cardiovascular or stroke event in the past 6 months, or known allergies to planned medications.
• For the gene therapy group: cases where the gene therapy did not result in restored hearing. For the cochlear implant group: people with hereditary syndromic deafness or other conditions that would seriously affect how results are measured (confirm with trial site).
• Anyone the trial investigators consider unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.